Phathom Pharmaceuticals, Inc. (PHAT) NASDAQ

8.71

+0.09(+1.04%)

Updated at July 30 04:00PM

Currency In USD

Phathom Pharmaceuticals, Inc.

Address

100 Campus Drive

Florham Park, NJ 07932

United States of America

Phone

877 742 8466

Sector

Healthcare

Industry

Biotechnology

Employees

427

First IPO Date

October 25, 2019

Key Executives

NameTitlePayYear Born
Mr. Steven L. Basta M.B.A.Chief Executive Officer, President & Director01966
Mr. David A. SocksCo-Founder & Director54,1671975
Ms. Molly Henderson CPA, MBAChief Financial & Business Officer777,7631971
Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder & Chief Operating Officer888,8971960
Mr. Martin J. GilliganChief Commercial Officer0N/A
Mr. Tom HarrisChief Development Sciences Officer0N/A
Mr. Jonathan BentleySenior Vice President & Head of Sales0N/A
Mr. Paul CocjaChief People Officer0N/A
Dr. Eckhard Leifke M.D., Ph.D.Chief Medical Officer0N/A

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.